#WCLC24 Highlights #CommunityOncology:

1. #HARMONi2 in mNSCLC

2. #CM77TvsCM816 resectable NSCLC

3. #TROPIONLung01 in 2L mNSCLC

4. #SKIPPirr: AEs for Amivantamab

5. #TNM staging: 9th Ed

6. Personal highlights

#lcsm #OncTwitter @IASLC

1/7 1. #HARMONi2: 1L #ivonescimab (PD1/VEGF bispecific) mNSCLC PDL1 ≥ 1% vs Pembro alone.

- mPFS of 11.14 vs 5.8 mos
- ⬆️ PFS for PDL1 ≥ 50% (HR: 0.46)
- ⬆️ PFS for PDL1 1-49% (HR: 0.54), but SoC is Pembro + Chemo (🚫 single agent Pembro)
- 🇨🇳 only study, will need 🌎 study

2/7

https://twitter.com/drriyazshah/status/1832807001229054376

Day 3 #GI23 Highlights #CommunityOncology

1. #MOUNTAINEER: Tucat+Trast approved CRC

2. #SUNLIGHT: TAS102+Bev confirmed late option CRC

3. #E2211: Cape+Tem in pNET manuscript

4. #ctDNA kinetics CRC

5. TNT state in RectalCA

@ASCO #OncEd #MedEd @OncoAlert #GISM #MedTwitter 1. #MOUNTAINEER: Tucatinib + Trastuzumab now @US_FDA approved for RAS WT, HER2+ve mCRC that has progressed on upfront chemo:

- ORR 38%
- mDOR 12.4mos
- Common AEs: diarrhea, fatigue, rash, and pyrexia.

https://x.com/pashtoonkasi/status/1616413330926886912

#WCLC22 Highlights #CommunityOncology perspective:

1. #YESS Study - @RachM_UoN

2. #IMPower010 Update

3. #CALGB140503 - Sublobar resection

4. #SHAWL Study - @NarjustFlorezMD @jillfeldman4

5. #NADIM2 Trial by @MARIANOPROVENCI

1/6

#LCSM #MedTwitter @OncoAlert #OncEd @IASLC 1. #YESS Study @RachM_UoN: Lung CA screening with smoking cessation intervention concurrently:

- Smoking cessation is one of the most effective way to reduce lung CA mortality
- 33% quit at 3 months
- Women more likely to benefit

2/6